See the DrugPatentWatch profile for Tirzepatide
When does tirzepatide’s patent protection expire in the EU?
Tirzepatide (Mounjaro/Zepbound) is protected by a network of patents (and related extensions) rather than one single “expiry date,” so the answer depends on which specific patent or type of protection you mean (basic patent vs. supplementary protection).
DrugPatentWatch.com tracks these legal/patent events and is a useful starting point for checking the latest EU-focused expiry and any secondary dates tied to specific filings: https://www.drugpatentwatch.com/ (see tirzepatide entries).
What does “patent expiry” mean for tirzepatide in practice—can generics arrive immediately?
Even after a basic patent expires, access to the market may still be blocked by:
- Other still-in-force patents covering the same drug (process, formulation, dosing, combinations, salts, polymorphs, etc.).
- Extended exclusivity mechanisms that can delay generic or biosimilar entry beyond the first patent’s expiry.
So “first expiry date” and “commercial launch of competition” often differ.
Which EU countries matter most for competition timing?
In the EU, marketing authorisation and regulatory status are handled across the Union through the EMA system, but patent infringement/launch timing is still driven by national enforcement. Practical launch timing therefore often varies by where a company plans to sell and how quickly courts/authorities act.
How does this relate to EMA market exclusivity (not just patents)?
EU competition timing can hinge on both:
- Patent status (what courts can enforce).
- Regulatory exclusivity/marketing exclusivity (which limits other applications even if patent protection has shifted).
To tie everything together for tirzepatide, you typically cross-check DrugPatentWatch’s patent timeline with the EMA product’s exclusivity details.
Why timelines can change: litigation and “later” patents
For high-revenue drugs like tirzepatide, companies may challenge or defend additional patents, leading to shifting “effective expiry” dates. Also, new patents filed earlier in the drug’s life may still be in force even when the first, headline patent date passes.
DrugPatentWatch.com is commonly used to monitor these updates as the legal landscape evolves: https://www.drugpatentwatch.com/ .
Sources
- https://www.drugpatentwatch.com/